X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-12-23 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% | S - Sale+OE | $6.28 | -11,671 | 795,824 | -1% | -$73,345 | |||||
2025-12-30 | IMNM | Immunome Inc. | Siegall Clay B | Pres, CEO | P - Purchase | $21.15 | +4,729 | 665,254 | +1% | +$100,018 | ||||||
2025-12-23 | ALZN | Alzamend Neuro, Inc. | Ault Milton C III | Dir | S - Sale | $2.07 | -1,851 | 19,389 | -9% | -$3,825 | ||||||
| D | 2025-12-29 | ARWR | Arrowhead Pharmaceuticals, Inc. | Anzalone Christopher Richard | CEO | S - Sale+OE | $69.13 | -51,726 | 3,805,926 | -1% | -$3,575,575 | |||||
2025-12-26 | ARWR | Arrowhead Pharmaceuticals, Inc. | Ferrari Mauro | Dir | S - Sale | $70.00 | -7,530 | 69,053 | -10% | -$527,100 | ||||||
| EM | 2025-12-26 | MRUS | Merus N.V. | Genmab A/S | 10% | P - Purchase | $1.33 | +76,922,983 | 0 | -100% | +$102,411,145 | |||||
2025-12-29 | CYTK | Cytokinetics Inc | Callos Andrew | EVP, Chief Commercial Officer | S - Sale | $62.44 | -1,809 | 51,353 | -3% | -$112,954 | ||||||
| D | 2025-12-29 | UTHR | United Therapeutics Corp | Benkowitz Michael | Pres, COO | S - Sale+OE | $502.79 | -22,500 | 2,648 | -89% | -$11,312,710 | |||||
2025-12-30 | MBIO | Mustang Bio, Inc. | Herskowitz Neil | Dir | S - Sale | $0.96 | -247 | 145 | -63% | -$238 | ||||||
2025-12-30 | MBIO | Mustang Bio, Inc. | Chill Adam J. | Dir | S - Sale | $0.95 | -4 | 375 | -1% | -$4 | ||||||
2025-12-30 | MBIO | Mustang Bio, Inc. | Jin David | Dir | P - Purchase | $0.96 | +247 | 286 | +633% | +$238 | ||||||
| D | 2025-12-29 | CTNM | Contineum Therapeutics, Inc. | Watkins Tim | CMO, Head of Development | S - Sale+OE | $12.06 | -3,611 | 0 | -100% | -$43,558 | |||||
2025-12-23 | CTNM | Contineum Therapeutics, Inc. | Lorrain Daniel S. | Chief Scientific Officer | S - Sale | $12.23 | -4,170 | 171,234 | -2% | -$51,009 | ||||||
| M | 2025-12-26 | HYPD | Hyperion Defi, Inc. | Strahlman Ellen R | Dir | P - Purchase | $3.66 | +30,880 | 126,030 | +32% | +$113,091 | |||||
2025-12-26 | COGT | Cogent Biosciences, Inc. | Kearns Evan | GC | S - Sale | $38.70 | -65,000 | 109,398 | -37% | -$2,515,500 | ||||||
2025-12-26 | COGT | Cogent Biosciences, Inc. | Green John L. | CFO | S - Sale | $38.68 | -77,000 | 131,834 | -37% | -$2,978,360 | ||||||
2025-12-26 | COGT | Cogent Biosciences, Inc. | Sachs Jessica | Chief Medical Officer | S - Sale | $38.70 | -82,642 | 133,938 | -38% | -$3,198,245 | ||||||
2025-12-26 | COGT | Cogent Biosciences, Inc. | Robinson John Edward | Chief Scientific Officer | S - Sale | $38.74 | -90,000 | 140,002 | -39% | -$3,486,600 | ||||||
| E | 2025-12-29 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $0.30 | -3,593 | 92,190,516 | 0% | -$1,085 | |||||
2025-12-29 | RARE | Ultragenyx Pharmaceutical Inc. | Huizenga Theodore Alan | SVP, Chief Accounting Officer | S - Sale | $34.38 | -85 | 50,450 | 0% | -$2,922 | ||||||
2025-12-22 | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | Dir | S - Sale | $28.53 | -2,881 | 858,287 | 0% | -$82,195 | ||||||
2025-12-24 | TVTX | Travere Therapeutics, Inc. | Heerma Peter | Chief Commercial Officer | S - Sale | $40.00 | -4,980 | 113,013 | -4% | -$199,200 | ||||||
| D | 2025-12-24 | TVTX | Travere Therapeutics, Inc. | Rote William E. | Chief Research Officer | S - Sale+OE | $40.10 | -60,000 | 101,443 | -37% | -$2,406,180 | |||||
| D | 2025-12-24 | TVTX | Travere Therapeutics, Inc. | Inrig Jula | Chief Medical Officer | S - Sale+OE | $42.00 | -15,000 | 88,787 | -14% | -$630,005 | |||||
| D | 2025-12-23 | ROIV | Roivant Sciences Ltd. | Pulik Richard | CFO | S - Sale+OE | $22.43 | -406,731 | 239,413 | -63% | -$9,122,307 | |||||
| DM | 2025-12-23 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $22.47 | -275,000 | 1,654,597 | -14% | -$6,179,750 | |||||
2025-12-24 | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | SVP, Chief Accounting Officer | S - Sale | $40.00 | -7,402 | 38,233 | -16% | -$296,080 | ||||||
2025-12-24 | SION | Sionna Therapeutics, Inc. | Orbimed Advisors LLC | Dir | S - Sale | $44.55 | -33,356 | 3,561,655 | -1% | -$1,486,010 | ||||||
2025-12-24 | SION | Sionna Therapeutics, Inc. | Thompson Peter A. | Dir | S - Sale | $44.55 | -33,356 | 3,561,655 | -1% | -$1,486,010 | ||||||
| M | 2025-12-23 | BNTC | Benitec Biopharma Inc. | Suvretta Capital Management, LLC | Dir, 10% | P - Purchase | $13.20 | +144,223 | 1,848,156 | +8% | +$1,903,133 | |||||
2025-12-22 | EOLS | Evolus, Inc. | Moatazedi David | See Remarks | S - Sale | $7.15 | -10,539 | 354,388 | -3% | -$75,361 | ||||||
2025-12-22 | EOLS | Evolus, Inc. | Avelar Rui | See Remarks | S - Sale | $7.15 | -2,261 | 356,821 | -1% | -$16,168 | ||||||
| M | 2025-12-22 | HOWL | Werewolf Therapeutics, Inc. | Evnin Luke | Dir | S - Sale | $0.64 | -291,283 | 2,550,674 | -10% | -$185,221 | |||||
| M | 2025-12-22 | MRUS | Merus N.V. | Genmab A/S | 10% | P - Purchase | $97.00 | +815,444 | 72,828,509 | +1% | +$79,098,068 | |||||
| DM | 2025-12-23 | NAMS | Newamsterdam Pharma Co N.V. | Kooij Louise Frederika | Chief Accounting Officer | S - Sale+OE | $35.84 | -145,000 | 15,000 | -91% | -$5,196,741 | |||||
2025-12-26 | RPRX | Royalty Pharma Plc | Urist Marshall | EVP, Research, Investments | S - Sale | $39.32 | -20,000 | 126,418 | -14% | -$786,380 | ||||||
| D | 2025-12-24 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $513.18 | -11,000 | 36,781 | -23% | -$5,644,954 | |||||
| D | 2025-12-22 | UTHR | United Therapeutics Corp | Benkowitz Michael | Pres, COO | S - Sale+OE | $514.35 | -22,500 | 2,648 | -89% | -$11,572,963 | |||||
2025-12-24 | PTN | Palatin Technologies Inc | Wills Stephen T | EVP, CFO, COO | S - Sale | $16.74 | -565 | 63,488 | -1% | -$9,461 | ||||||
2025-12-29 | ABEO | Abeona Therapeutics Inc. | Seshadri Vishwas | CEO | S - Sale | $5.31 | -25,000 | 1,164,818 | -2% | -$132,740 | ||||||
2025-12-23 | TXMD | Therapeuticsmd, Inc. | Thompson Tommy G | Dir | P - Purchase | $1.67 | +8,400 | 37,512 | +29% | +$14,031 | ||||||
2025-12-29 | ALT | Altimmune, Inc. | Jorkasky Diane | Dir | P - Purchase | $3.80 | +527 | 527 | New | +$2,003 | ||||||
| D | 2025-12-24 | DVAX | Dynavax Technologies Corp | Novack David F | Pres, COO | S - Sale+OE | $15.49 | -30,000 | 63,344 | -32% | -$464,700 | |||||
| M | 2025-12-22 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% | P - Purchase | $41.49 | +2,905 | 387,435 | +1% | +$120,533 | |||||
| E | 2025-12-24 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $0.41 | -2,629 | 92,194,109 | 0% | -$1,085 | |||||
| E | 2025-12-23 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $4.52 | -240 | 92,196,738 | 0% | -$1,085 | |||||
2025-12-24 | VSTM | Verastem, Inc. | Calkins Daniel | CFO | S - Sale | $7.86 | -80 | 109,758 | 0% | -$629 | ||||||
2025-12-26 | MNPR | Monopar Therapeutics | Vu Quan Anh | CFO | P - Purchase | $69.95 | +1,500 | 1,500 | New | +$104,925 | ||||||
| D | 2025-12-23 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Chief Scientific Officer | S - Sale+OE | $2.60 | -4,100 | 0 | -100% | -$10,660 | |||||
| M | 2025-12-24 | COCP | Cocrystal Pharma, Inc. | Frost Phillip Md Et Al | Dir, 10% | P - Purchase | $0.97 | +65,000 | 1,795,651 | +4% | +$63,202 | |||||
2025-12-23 | PHIO | Phio Pharmaceuticals Corp. | Bitterman Robert J | COB, Pres, CEO | P - Purchase | $1.02 | +5,000 | 286,421 | +2% | +$5,100 | ||||||
| D | 2025-12-19 | OLMA | Olema Pharmaceuticals, Inc. | Clark Ian T | Dir | S - Sale+OE | $29.73 | -264,800 | 0 | -100% | -$7,873,109 | |||||
2025-12-19 | OLMA | Olema Pharmaceuticals, Inc. | Myles David C. | CH. DISCOV., NON-CLIN DEV OFF | S - Sale | $30.46 | -51,000 | 710,558 | -7% | -$1,553,544 | ||||||
| DM | 2025-12-19 | OLMA | Olema Pharmaceuticals, Inc. | Zojwalla Naseem | Chief Medical Officer | S - Sale+OE | $27.94 | -269,509 | 4,488 | -98% | -$7,530,148 | |||||
2025-12-23 | AMLX | Amylyx Pharmaceuticals, Inc. | Firestone Karen | Dir | P - Purchase | $12.45 | +8,100 | 63,100 | +15% | +$100,845 | ||||||
2025-12-22 | OKUR | Onkure Therapeutics, Inc. | Saccomano Nicholas A | Pres, CEO | S - Sale | $2.97 | -87 | 7,419 | -1% | -$258 | ||||||
2025-12-22 | OKUR | Onkure Therapeutics, Inc. | Leverone Jason A. | CFO | S - Sale | $2.97 | -302 | 16,301 | -2% | -$896 | ||||||
| D | 2025-12-22 | MIRM | Mirum Pharmaceuticals, Inc. | Ramasastry Saira | Dir | S - Sale+OE | $80.00 | -5,000 | 0 | -100% | -$400,000 | |||||
| D | 2025-12-19 | MIRM | Mirum Pharmaceuticals, Inc. | Grey Michael G | Dir | S - Sale+OE | $78.00 | -50,000 | 280,160 | -15% | -$3,900,000 | |||||
2025-12-19 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S - Sale | $16.84 | -5,000 | 897,688 | -1% | -$84,206 | ||||||
2025-12-19 | ARWR | Arrowhead Pharmaceuticals, Inc. | Waddill William D. | Dir | S - Sale | $67.65 | -8,367 | 56,563 | -13% | -$566,038 | ||||||
2025-12-19 | ARWR | Arrowhead Pharmaceuticals, Inc. | Vakiener Victoria | Dir | S - Sale | $67.68 | -10,040 | 35,723 | -22% | -$679,491 | ||||||
| M | 2025-12-19 | ARWR | Arrowhead Pharmaceuticals, Inc. | Anzalone Christopher Richard | CEO | S - Sale | $68.04 | -26,031 | 3,805,926 | -1% | -$1,771,022 | |||||
2025-12-19 | ARWR | Arrowhead Pharmaceuticals, Inc. | Olukotun Adeoye Y | Dir | S - Sale | $67.66 | -10,000 | 33,600 | -23% | -$676,623 | ||||||
| D | 2025-12-19 | PTCT | Ptc Therapeutics, Inc. | Pauwels Eric | CHIEF BUSINESS OFFICER | S - Sale+OE | $77.26 | -20,508 | 70,373 | -23% | -$1,584,350 | |||||
2025-12-22 | IMNM | Immunome Inc. | Barchas Isaac | Dir | S - Sale | $21.74 | -383,200 | 4,165,824 | -8% | -$8,330,080 | ||||||
| M | 2025-12-19 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% | S - Sale | $6.49 | -9,949 | 383,201 | -3% | -$64,564 | |||||
2025-12-23 | UTHR | United Therapeutics Corp | Malcolm Jan | Dir | S - Sale | $512.12 | -50 | 420 | -11% | -$25,606 | ||||||
| D | 2025-12-22 | UTHR | United Therapeutics Corp | Sullivan Louis W | Dir | S - Sale+OE | $512.14 | -5,950 | 3,200 | -65% | -$3,047,201 | |||||
2025-12-23 | ANAB | Anaptysbio, Inc | Ware J. Anthony | Dir | S - Sale | $49.58 | -3,900 | 9,630 | -29% | -$193,343 | ||||||
2025-12-19 | ALZN | Alzamend Neuro, Inc. | Horne William B. | Dir | S - Sale | $2.12 | -3,333 | 0 | -100% | -$7,059 | ||||||
| D | 2025-12-22 | ANAB | Anaptysbio, Inc | Lizzul Paul F. | Chief Medical Officer | S - Sale+OE | $50.00 | -1,500 | 26,967 | -5% | -$75,000 | |||||
| D | 2025-12-22 | ANAB | Anaptysbio, Inc | Mulroy Dennis | CFO | S - Sale+OE | $50.00 | -10,000 | 9,401 | -52% | -$500,000 | |||||
| D | 2025-12-22 | ANAB | Anaptysbio, Inc | Loumeau Eric J | GC | S - Sale+OE | $51.00 | -10,000 | 8,947 | -53% | -$510,000 | |||||
| D | 2025-12-23 | EQ | Equillium, Inc. | Zedelmayer Christine | SVP, COO | S - Sale+OE | $1.50 | -100,000 | 91,444 | -52% | -$150,000 | |||||
2025-12-19 | FOLD | Amicus Therapeutics, Inc. | Clark David Michael | Chief People Officer | S - Sale | $14.17 | -25,642 | 245,690 | -9% | -$363,380 | ||||||
| D | 2025-12-22 | CYTK | Cytokinetics Inc | Wierenga Wendell | Dir | S - Sale+OE | $66.14 | -20,000 | 32,444 | -38% | -$1,322,800 | |||||
2025-12-23 | ALT | Altimmune, Inc. | Gill John | Dir | P - Purchase | $4.10 | +12,500 | 12,500 | New | +$51,250 | ||||||
| D | 2025-12-22 | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | CFO | S - Sale+OE | $18.31 | -9,200 | 145,355 | -6% | -$168,492 | |||||
| D | 2025-12-19 | XNCR | Xencor Inc | Desjarlais John R | SVP, CSO | S - Sale+OE | $15.72 | -73,367 | 242,885 | -23% | -$1,153,329 | |||||
| D | 2025-12-19 | XNCR | Xencor Inc | Dahiyat Bassil I | Pres, CEO | S - Sale+OE | $15.71 | -114,377 | 477,259 | -19% | -$1,796,863 | |||||
| D | 2025-12-22 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Chief Scientific Officer | S - Sale+OE | $2.67 | -5,673 | 0 | -100% | -$15,168 | |||||
| A | 2025-12-23 | GALT | Galectin Therapeutics Inc | Freeman Kevin D | Dir | P - Purchase | $3.55 | +5,500 | 153,332 | +4% | +$19,514 | |||||
| A | 2025-12-23 | GALT | Galectin Therapeutics Inc | Freeman Kevin D | Dir | P - Purchase | $3.55 | +5,500 | 137,269 | +4% | +$19,514 | |||||
2025-12-23 | GALT | Galectin Therapeutics Inc | Eldred Kary | Dir | P - Purchase | $3.73 | +700 | 69,807 | +1% | +$2,611 | ||||||
2025-12-23 | GALT | Galectin Therapeutics Inc | Freeman Kevin D | Dir | P - Purchase | $3.55 | +5,500 | 137,269 | +4% | +$19,514 | ||||||
2025-12-23 | GALT | Galectin Therapeutics Inc | Eldred Kary | Dir | P - Purchase | $3.73 | +700 | 69,807 | +1% | +$2,611 | ||||||
| D | 2025-12-22 | MAIA | Maia Biotechnology, Inc. | Smith Stan | Dir | P - Purchase | $1.22 | +57,189 | 1,435,218 | +4% | +$69,999 | |||||
| D | 2025-12-22 | MAIA | Maia Biotechnology, Inc. | Chaouki Steven M | Dir | P - Purchase | $1.22 | +40,849 | 151,873 | +37% | +$49,999 | |||||
| D | 2025-12-22 | MAIA | Maia Biotechnology, Inc. | Louie Ngar Yee | Dir | P - Purchase | $1.22 | +81,699 | 1,248,888 | +7% | +$100,000 | |||||
2025-12-22 | PGEN | Precigen, Inc. | Kirk Randal J | Dir, 10% | S - Sale | $4.18 | -1,900,036 | 122,046,184 | -2% | -$7,942,150 | ||||||
| M | 2025-12-18 | BNTC | Benitec Biopharma Inc. | Suvretta Capital Management, LLC | Dir, 10% | P - Purchase | $11.68 | +46,141 | 1,826,653 | +3% | +$538,972 | |||||
| D | 2025-12-22 | ZYME | Zymeworks Inc. | Galbraith Kenneth | Chair, CEO | S - Sale+OE | $27.02 | -47,528 | 133,275 | -26% | -$1,284,311 | |||||
| M | 2025-12-18 | MRUS | Merus N.V. | Genmab A/S | 10% | P - Purchase | $97.00 | +278,441 | 72,013,065 | 0% | +$27,008,777 | |||||
2025-12-18 | LITS | Lite Strategy, Inc. | Schornstein Alexander | 10% | S - Sale | $1.37 | -690,611 | 3,674,862 | -16% | -$946,137 | ||||||
2025-12-22 | ALT | Altimmune, Inc. | Durso Jerome Benedict | Dir | P - Purchase | $4.13 | +12,500 | 12,500 | New | +$51,569 | ||||||
2025-12-19 | RPRX | Royalty Pharma Plc | Urist Marshall | EVP, Research, Investments | S - Sale | $38.38 | -20,000 | 146,418 | -12% | -$767,582 | ||||||
| D | 2025-12-19 | SUPN | Supernus Pharmaceuticals, Inc. | Mottola Frank | SVP, Chief Tech. Ops. Officer | S - Sale+OE | $50.41 | -20,000 | 15,496 | -56% | -$1,008,150 | |||||
2025-12-19 | LITS | Lite Strategy, Inc. | Flynn James P | Dir | P - Purchase | $1.40 | +70,000 | 100,000 | +233% | +$97,699 | ||||||
2025-12-18 | HYPD | Hyperion Defi, Inc. | Strahlman Ellen R | Dir | P - Purchase | $3.14 | +38,444 | 170,598 | +29% | +$120,664 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |